QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.

The main molecular features which determine the selectivity of a set of 80 N-hydroxy-alpha-phenylsulfonylacetamide derivatives (HPSAs) in the inhibition of three matrix metalloproteinases (MMP-1, MMP-9, and MMP-13) have been identified by using linear and nonlinear predictive models. The molecular information has been encoded in 2D autocorrelation descriptors, obtained from different weighting schemes. The linear models were built by multiple linear regression (MLR) combined with genetic algorithm (GA), and a robust QSAR mapping paradigm. The Bayesian-regularized genetic neural network (BRGNN) was employed for nonlinear modeling. In such approaches each model could have its own set of input variables. All models were predictive according to internal and external validation experiments; but the best results correspond to nonlinear ones. The 2D autocorrelation space brings different descriptors for each MMP inhibition, and suggests the atomic properties relevant for the inhibitors to interact with each MMP active site. On the basis of the current results, the reported models have the potential to discover new potent and selective inhibitors and bring useful molecular information about the ligand specificity for MMP S(1)(') and S(2)(') subsites.

[1]  Julio Caballero,et al.  2D Autocorrelation modeling of the negative inotropic activity of calcium entry blockers using Bayesian-regularized genetic neural networks. , 2006, Bioorganic & medicinal chemistry.

[2]  Julio Caballero,et al.  Bayesian-regularized genetic neural networks applied to the modeling of non-peptide antagonists for the human luteinizing hormone-releasing hormone receptor. , 2006, Journal of molecular graphics & modelling.

[3]  Julio Caballero,et al.  Linear and nonlinear modeling of antifungal activity of some heterocyclic ring derivatives using multiple linear regression and Bayesian-regularized neural networks , 2006, Journal of molecular modeling.

[4]  Rajarshi Guha,et al.  Interpreting Computational Neural Network Quantitative Structure-Activity Relationship Models: A Detailed Interpretation of the Weights and Biases , 2005, J. Chem. Inf. Model..

[5]  Bahram Hemmateenejad,et al.  Genetic Algorithm Applied to the Selection of Factors in Principal Component-Artificial Neural Networks: Application to QSAR Study of Calcium Channel Antagonist Activity of 1, 4-Dihydropyridines (Nifedipine Analogous) , 2003, J. Chem. Inf. Comput. Sci..

[6]  Bahram Hemmateenejad,et al.  Application of ab initio theory to QSAR study of 1,4‐dihydropyridine‐based calcium channel blockers using GA‐MLR and PC‐GA‐ANN procedures , 2004, J. Comput. Chem..

[7]  Julio Caballero,et al.  2D Autocorrelation modeling of the activity of trihalobenzocycloheptapyridine analogues as farnesyl protein transferase inhibitors , 2005 .

[8]  A. H. Drummond,et al.  Recent advances in matrix metalloproteinase inhibitor research , 1996 .

[9]  R. Geary,et al.  The Contiguity Ratio and Statistical Mapping , 1954 .

[10]  H. V. Van Wart,et al.  Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors , 1999, Nature Structural Biology.

[11]  A. Tropsha,et al.  Beware of q2! , 2002, Journal of molecular graphics & modelling.

[12]  John Ellingboe,et al.  Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. , 2003, Journal of medicinal chemistry.

[13]  S. Shapiro,et al.  Matrix metalloproteinase degradation of extracellular matrix: biological consequences. , 1998, Current opinion in cell biology.

[14]  Julio Caballero,et al.  Linear and nonlinear QSAR study of N-hydroxy-2-[(phenylsulfonyl)amino]acetamide derivatives as matrix metalloproteinase inhibitors. , 2006, Bioorganic & medicinal chemistry.

[15]  S. Gupta,et al.  A quantitative structure-activity relationship study on some series of anthranilic acid-based matrix metalloproteinase inhibitors. , 2005, Bioorganic & medicinal chemistry.

[16]  A Comparative QSAR Study on Carbonic Anhydrase and Matrix Metalloproteinase Inhibition by Sulfonylated Amino Acid Hydroxamates , 2003, Journal of enzyme inhibition and medicinal chemistry.

[17]  Elizabeth A. Amin,et al.  Highly Predictive CoMFA and CoMSIA Models for Two Series of Stromelysin-1 (MMP-3) Inhibitors Elucidate S1' and S1-S2' Binding Modes , 2006, J. Chem. Inf. Model..

[18]  Douglas M. Hawkins,et al.  The Problem of Overfitting , 2004, J. Chem. Inf. Model..

[19]  M. Cronin,et al.  Pitfalls in QSAR , 2003 .

[20]  F. Burden,et al.  Robust QSAR models using Bayesian regularized neural networks. , 1999, Journal of medicinal chemistry.

[21]  D. Rappolee,et al.  Basement Membrane and Repair of Injury to Peripheral Nerve: Defining a Potential Role for Macrophages, Matrix Metalloproteinases, and Tissue Inhibitor of Metalloproteinases-1 , 1996, The Journal of experimental medicine.

[22]  Bahram Hemmateenejad,et al.  Toward an Optimal Procedure for PC-ANN Model Building: Prediction of the Carcinogenic Activity of a Large Set of Drugs , 2005, J. Chem. Inf. Model..

[23]  A quantitative structure–activity relationship study of hydroxamate matrix metalloproteinase inhibitors derived from funtionalized 4-aminoprolines , 2003 .

[24]  A quantitative structure-activity relationship study on Clostridium histolyticum collagenase inhibitors: roles of electrotopological state indices. , 2003, Bioorganic & medicinal chemistry.

[25]  D. Wilson,et al.  Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. , 1997, Journal of medicinal chemistry.

[26]  A. Gearing,et al.  Design and therapeutic application of matrix metalloproteinase inhibitors. , 1999, Chemical reviews.

[27]  S P Gupta,et al.  A quantitative structure-activity relationship study on some matrix metalloproteinase and collagenase inhibitors. , 2003, Bioorganic & medicinal chemistry.

[28]  Tingjun Hou,et al.  Molecular docking studies of a group of hydroxamate inhibitors with gelatinase-A by molecular dynamics , 2002, J. Comput. Aided Mol. Des..

[29]  Didier Villemin,et al.  Structure-musk odour relationship studies of tetralin and indan compounds using neural networks , 1998 .

[30]  Brian E. Mattioni,et al.  Prediction of dihydrofolate reductase inhibition and selectivity using computational neural networks and linear discriminant analysis. , 2003, Journal of molecular graphics & modelling.

[31]  S. Hanessian,et al.  Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors. , 1999, Bioorganic & medicinal chemistry letters.

[32]  W. Welsh,et al.  Three-dimensional quantitative structure-activity relationship (3D-QSAR) models for a novel class of piperazine-based stromelysin-1 (MMP-3) inhibitors: applying a "divide and conquer" strategy. , 2001, Journal of medicinal chemistry.

[33]  P. Moran.  Notes on continuous stochastic phenomena. , 1950, Biometrika.

[34]  David J. C. MacKay,et al.  Bayesian Interpolation , 1992, Neural Computation.

[35]  H. V. Van Wart,et al.  Understanding the P1' specificity of the matrix metalloproteinases: effect of S1' pocket mutations in matrilysin and stromelysin-1. , 1996, Biochemistry.

[36]  John Ellingboe,et al.  Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. , 2003, Journal of medicinal chemistry.

[37]  Stephen Hanessian,et al.  A comparative docking study and the design of potentially selective MMP inhibitors , 2001, J. Comput. Aided Mol. Des..

[38]  David J. C. MacKay,et al.  A Practical Bayesian Framework for Backpropagation Networks , 1992, Neural Computation.

[39]  Martin T. Hagan,et al.  Gauss-Newton approximation to Bayesian learning , 1997, Proceedings of International Conference on Neural Networks (ICNN'97).

[40]  David T. Stanton,et al.  On the Physical Interpretation of QSAR Models , 2003, J. Chem. Inf. Comput. Sci..

[41]  R. Powers,et al.  The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position. , 2001, Bioorganic & medicinal chemistry letters.

[42]  M Karplus,et al.  Evolutionary optimization in quantitative structure-activity relationship: an application of genetic neural networks. , 1996, Journal of medicinal chemistry.